Rein Therapeutics rises as drug for lung‑scarring disease gets EU orphan status

Shares of drug developer Rein Therapeutics RNTX.O rise 2.5% to $1.24 premarket

 Co says European regulators granted orphan drug status to its experimental therapy, LTI‑03, for idiopathic pulmonary fibrosis or IPF, a fatal lung‑scarring disease

IPF causes irreversible lung damage that makes breathing difficult

Co says early data from preclinical tests showed better survival and lung function

RNTX's LTI‑03 is a synthetic peptide aimed at protecting lung cells and blocking signals that drive scarring; drug also holds U.S. orphan status, co says

Co plans further trials in the U.S., UK, Germany, Poland and Australia

As of last close, stock declined ~50% over the past year